REBECCA ERUPE: Open Payments
NPI 1407570906 · LEEDS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 25 payments from 9 companies in 2025. Trend: 2023 $76 · 2024 $835 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $217 |
| E.R. Squibb & Sons, L.L.C. | 4 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Neurocrine BioSciences, Inc. | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Alkermes, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $19 |
Products named: VRAYLAR, COBENFY, CAPLYTA, INGREZZA, FANAPT, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across MA — which companies pay providers there.
